About voyager therapeutics - VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
VYGR At a Glance
Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, Massachusetts 02421
| Phone | 1-857-259-5340 | Revenue | 250.01M | |
| Industry | Biotechnology | Net Income | 132.33M | |
| Sector | Health Technology | 2023 Sales Growth | 511.162% | |
| Fiscal Year-end | 12 / 2024 | Employees | 162 | |
| View SEC Filings |
VYGR Valuation
| P/E Current | 24.468 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.843 |
| Price to Sales Ratio | 1.505 |
| Price to Book Ratio | 1.573 |
| Price to Cash Flow Ratio | 4.828 |
| Enterprise Value to EBITDA | 1.309 |
| Enterprise Value to Sales | 0.662 |
| Total Debt to Enterprise Value | 0.123 |
VYGR Efficiency
| Revenue/Employee | 1,543,259.259 |
| Income Per Employee | 816,851.852 |
| Receivables Turnover | 2.96 |
| Total Asset Turnover | 0.979 |
VYGR Liquidity
| Current Ratio | 4.956 |
| Quick Ratio | 4.956 |
| Cash Ratio | 3.579 |
VYGR Profitability
| Gross Margin | 98.224 |
| Operating Margin | 48.804 |
| Pretax Margin | 53.493 |
| Net Margin | 52.93 |
| Return on Assets | 51.829 |
| Return on Equity | 89.612 |
| Return on Total Capital | 51.568 |
| Return on Invested Capital | 79.543 |
VYGR Capital Structure
| Total Debt to Total Equity | 8.587 |
| Total Debt to Total Capital | 7.908 |
| Total Debt to Total Assets | 5.777 |
| Long-Term Debt to Equity | 7.233 |
| Long-Term Debt to Total Capital | 6.661 |